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Abstract
Background: Procalcitonin is an inflammatory biomarker that is sensitive for bacterial infections and a promising
clinical decision aid in antimicrobial stewardship programs. However, there are few studies of physicians’
experiences concerning the use of PCT. The objective of this study was to investigate whether hospital physicians’
experience with procalcitonin after 18 months of use can inform the PCT implementation in antimicrobial
stewardship programs.
Materials/methods: We deployed a qualitative approach using semi-structured interviews with 14 hospital
physicians who had experience with procalcitonin in clinical practice. Interviews were audio-taped, transcribed
verbatim and analysed using thematic analysis.
Results: Physicians reported a knowledge gap, which made them uncertain about the appropriate procalcitonin
use, interpretation, and trustworthiness. Simultaneously, the physicians experienced procalcitonin as a useful clinical
decision aid but emphasised that their clinical evaluation of the patient was the most important factor when
deciding on antibiotic treatment.
Conclusions: Procalcitonin was regarded a helpful clinical tool, but the physicians called for more knowledge
about its appropriate uses. Active implementation of unambiguous procalcitonin algorithms and physician
education may enhance the utility of the test as an antimicrobial stewardship adjunct.
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Introduction
Antimicrobial resistance (AMR) is a global health threat
[1]. As one of several countermeasures, hospitals world-
wide have established antimicrobial stewardship programs
(ASPs) [2]. ASPs may be defined as “a coherent set of ac-
tions which promote using antimicrobials responsibly” [3].
One such potential action is to implement procalcitonin
(PCT) as a clinical decision aid to improve antibiotic use.
PCT is a biomarker that increases in response to bacterial
rather than viral stimuli. Moreover, it rises rapidly after in-
flammatory stimuli (4–6 h) and has a short half-life of 24
h [4]. It has also been introduced in antibiotic stewardship
as a decision aid to withhold antibiotic prescriptions and
to reduce the duration of antibiotic treatment for various
infections, without compromising patient safety [5, 6], in
particular for patients with lower respiratory tract infec-
tions and sepsis [7, 8].
By 2017, most Norwegian hospitals had started to im-
plement ASPs [9], and PCT was introduced in our hos-
pital. However, in a recent survey of PCT routines in
Norwegian hospitals, we found that 27 out of 28 hospi-
tals (96%) used PCT, but only five (18%) had imple-
mented PCT for ASP use, and none had done this
proactively. Furthermore, only two institutions (7%) had
systematically evaluated how PCT was used (unpub-
lished data, J. B Haug, I. Christensen). Additionally, the
adherence to PCT algorithms is generally low, of which
the reasons are only partly understood [10–12]. There is
consequently a need to explore physicians’ PCT use in
more detail to improve the understanding of their be-
haviour and culture, which is recognised as essential in
the development of sustainable ASPs [13–15]. This study
aimed to investigate whether hospital physicians’ experi-
ence with PCT after 18 months of use can inform the
PCT implementation in ASPs.
Materials and methods
Design and setting
This qualitative study, using semi-structured interviews,
was conducted at Østfold Hospital Trust, a 380-bed
acute care hospital in south-eastern Norway. As PCT
was introduced in the hospital in April 2017, an anti-
biotic stewardship team had recently been established.
At the time, this team mainly conducted surveillance of
antibiotic use, revised guidelines and offered education
on antibiotic use. ASP team members educated the hos-
pital’s physicians in internal meetings on how to use the
PCT assay, and a clinical algorithm was presented
(Table 1) but insufficient resources were available to ac-
tive follow up the physicians’ compliance. The hospital
laboratory only referenced the standard electronic PCT
cut-off value of 0.1 μg/L along with the PCT results.
Due to cost restraints, the use of PCT was restricted
to intensive care, haematology, gastrointestinal surgery,
infectious and pulmonary disease departments. In the
following 18 months, the use of PCT was left to the phy-
sicians’ discretion. However, all physicians ordering PCT
were prompted to fill out an electronic form in the pa-
tient’s medical records, asking for information concern-
ing i) indication for PCT, ii) actions taken based on PCT
results, and iii) their subjective view on the value of the
test (Additional file 1). For the present study, the form
was used to map the actual PCT usage in our hospital
and give valuable information for the interview guide.
Recruitment and data collection
Potential informants were identified from the laboratory
database of PCT requesters. Included physicians (n = 14)
had requested a mean of 20 PCT tests compared to a
mean of four tests by the not-invited physicians (n =
219). An invitation to participate was not solely based
on the number of PCT requests, but by a joint judge-
ment by the authors IC and JBH of the candidates based
on diversity in medical experience and speciality. The
first author (IC) sent eligible physicians an email invita-
tion to participate in the study which contained informa-
tion about the aim and practical aspects of study
participation, including the need to reserve 60–90min of
uninterrupted interview time.
An interview guide (Summarised in Table 2, full ver-
sion in Additional file 2) was developed based on the lit-
erature [6, 10, 16, 17], and leveraged by the previously
mentioned electronic form (Additional file 1). Three
pilot interviews, with eligible physicians, were conducted
to optimise the final interview-guide and technique, but
were not included in the analysis.
All interviews were performed by IC (a female junior
doctor trained in qualitative methods, with clinical experi-
ence from surgery and oncology at the study hospital) and
Table 1 PCT algorithm recommended in internal meetings at
the PCT introduction
Intensive care unit (severe infections/sepsis)
PCT < 0.5 μg/ Antibiotics should be considered withdrawn
PCT≥ 0.5 μg/
L
In patients who have improved clinically, subsequent
PCT analyses are recommended on days 3 and 5.
A decrease of 80% of the initial value suggests that
antibiotics are no longer needed.
Respiratory tract infections (community-acquired pneumonia and
acute exacerbation of chronic obstructive pulmonary disease)
PCT < 0.1 μg/
L:




Encourage against the continuation of antibiotics
PCT 0.25–
0.5 μg/L:
Recommendation for continuing antibiotics
PCT > 0.5 μg/
L:
Strong recommendation for continuing antibiotics
Christensen et al. BMC Infectious Diseases          (2020) 20:515 Page 2 of 7
held in a quiet room at the hospital. The interview period
lasted from November 2018 to February 2019. Following
the 12th interview, no new themes were identified. To en-
sure saturation, we conducted two more interviews,
resulting in a total of 14 interviews. The mean interview
time was 52min (23-74min). Study participants included
five from infectious diseases, three from oncology, one
medical resident, and one from each of the following spe-
cialities: anaesthesiology, gastrointestinal surgery, gastro-
enterology, pulmonology, and haematology. Table 3
presents participant characteristics.
Data management and analysis
Interviews were audio-recorded, transcribed verbatim,
and de-identified (IC). Thematic analysis following the
recommendations of Braun and Clarke was performed
by IC and last co-author (LPJJ) [18]. IC scanned the
transcripts for illustrative quotes. Scrutiny of our posi-
tions, presumptions, and their possible influences on the
study process was continuously applied and written
down in a project log (reflexivity) [19].
Results
Two main themes were identified. Theme one, “know-
ledge gap”, consists of three subthemes: “unsure of use”,
“unsure of interpretation”, and “trustworthiness”. Theme
two, “diagnostic value”, consists of two subthemes: “sup-
porting decisions” and “clinical evaluation most import-
ant.” Themes, subthemes, and representative quotes are
presented in Table 4. After the quotes presented in the
text, the respondent number and years of experience is
given.
Theme one: knowledge gap
Unsure of use
Uncertainty was related to the actual use of the test, an
aspect that was reported both directly by the physicians
and through their descriptions of clinical situations. In
particular, uncertainty was expressed as to which indica-
tions it was appropriate to use PCT: “It (PCT) is not to
be used for all diagnoses, I don’t quite remember ( …) I
would like more experience; when is it indicated to use
it?” (R11, 22y). The physicians highlighted that uncer-
tainty of use was a driver for not trusting and using the
test more: “If we knew how to use it (PCT) correctly and
had more competence on its use ( …) then it could be
more helpful” (R13, 4y). Moreover, the test was infre-
quently used, so obtaining information about the test
from the scientific literature was not prioritised in a busy
clinical practice. The physicians that had consulted the
literature were still unsure due to diverse guidelines and
lack of familiarity with the test, advocating the need for
more experience: “I don’t have enough experience with it,
to verify it; we sort of have to test it, so I think time will
show” (R1, 12y).
Unsure of interpretation
Another area of uncertainty was on how to interpret the
test results. If clear-cut guidelines had been available, this
could have facilitated faster and more targeted decisions:
“If we had straightforward guidelines ( …) and knew that
when a patient with PCT above this or that level most
likely has sepsis, then it (PCT) would probably be pretty
helpful” (R13, 4y). When physicians encountered PCT
levels referred to as “median,” “in-between” or “borderline
values”, they fell short in interpreting the results: “I don’t
quite have a sense of it yet; what is actually really high,
what is low, and what is in between (values)?” (R8, 23y). In
fact, when left with “borderline values,” i.e. values which
the physicians were unsure of, they usually chose to give
antibiotic treatment “just in case.”
Trustworthiness
Several physicians reported experiences where the PCT
results had “scared,” “failed,” or “disappointed” them,
which led to uncertainty about the tests’ trustworthiness.
E.g., when the PCT result was surprisingly deviant from
their expectations based on the clinical picture: “We re-
cently had a patient where PCT increased to very high
levels, but we did not have any other indicators for
Table 3 Characteristics of study participants (n = 14)
Age (years)
Median (IQR) 36.5 (14.5)
Range 29–66
Hospital experience (n)
< 5 years 4
5–10 years 3
10–20 years 4





Table 2 Summarised interview guide (full version in
Additional file 2)
1. Can you please describe some of your experiences with the PCT-test?
2. Can you recall the first time you used PCT?
3. What are your expectations for the test?
4. According to the medical literature, there is no firm consensus on
PCT use. Could you describe how this matches your experiences?
5. Have you received any education or guidance on PCT uses?
6. Can you recall an episode when a PCT result was low, and you
decided to start or continue antibiotic treatment?
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infection ( …); therefore, we used the result to observe
that PCT is not the answer to everything” (R4, 25y).
Some reported frightening experiences;” it was a close
call that the patient survived; negative PCT and
pneumococcus in the aorta, but there was no sepsis (…).
THAT one scared us; it was completely negative PCT”
(R7, 13y). Such experiences led to a lack of confidence in
the test and, in some cases, physicians had stopped using
it. The majority of physicians, however, had continued
to use the test but applied it more cautiously.
Theme two: diagnostic value
Supporting decisions
Physicians found PCT supportive for clinical decision-
making involving infections, in particular when they re-
ferred to the results as either “very high” or “low,” as op-
posed to the “middle values.” Physicians framed this
support in various ways, for instance informant 4 (25y)
emphasised that PCT made him “brave enough to stop
antibiotics”, while others highlighted that it provided
“legal support” (R8, 23y), or “put more flesh on the bones”
(R13, 4y). They especially appreciated when the test sup-
ported their premade decision: “The clinical findings
may not be convincing with regard to infection, so we
order a PCT; if it is negative, we kind of get more support
to quit antibiotics” (R14, 1y). Several of the physicians
had experienced PCT as an additional tool to traditional
infection markers, such as C-reactive protein (CRP) and
leukocytes.
The physicians viewed PCT as particularly useful in
cancer patients. In these cases, clinical decisions were
often perceived as challenging since fever, impaired gen-
eral condition or increased CRP could relate to cancer
itself or an infection: “Increased CRP – it does not neces-
sarily mean an infection in cancer patients; in these
cases, PCT is a good tool to obtain an overall picture (
…)” (R6, 4y).
An unexpected PCT value also guided the physicians
to think more broadly and sometimes accelerated the
diagnostic process. For example, looking for rheumatolo-
gically or malignant disorders when the result was lower
than expected, or for infection when the result was
higher than expected: “In one patient, we were in some
doubt about a possible rheumatic condition ( …); then,
we requested a PCT which turned out to be 17, which led
us to look more thoroughly for an infection” (R11, 22).
Clinical evaluation most important
Although PCT was viewed as a contribution to the diag-
nostic toolbox, it was not a standalone test. Some had
felt great enthusiasm when it was introduced, but as they
gained experience, they realised that PCT could not re-
place clinical judgement. The patient’s clinical appear-
ance remained the most important basis for decisions: “I
do not feel PCT is the answer to everything, we have to
Table 4 Themes, subthemes and illustrative quotes
Example quotes (informant number, clinicians’ years of experience) Subtheme Theme
My experience is that no one can actually say something certain about it (PCT). We use it and it guides us to some
degree (…) but we don’t trust it 100% (R10, 16y)
It (PCT) is possibly indicated in several cases, but I don’t know them, so I think more knowledge about it would be
effective (R14, 1y)
What you don’t use you don’t get good at; I see up to 100 CRP values every day so of course I can interpret CRP,
while I encounter a PCT maybe only twice a week (R2, 18y)
Unsure of use Knowledge
gap
When I get the result, I have no clue what it means. Then I ask colleagues, and they just “no, we don’t quite know
what it means, don’t know if we can trust it, don’t know whether it increases or decreases in certain infections” (R5,
4y)
If someone had informed us how to interpret the (PCT) results for this patient group (cancer), it would of course
have been a great help and I believe it would have made us a little more confident when using the test (R1, 12y)
Unsure of
interpretation
I am not sure I would trust PCT in all diagnoses. The other day in geriatrics there was a lady with a HUGE intra-
abdominal abscess, she had a PCT which was 0.25, which isn’t much (R11, 22y)
I’ve gotten surprised once in a while when I’ve used PCT e.g. on patients receiving immunotherapy; they are admitted
with suspected infection, but it is actually adverse effects of the immunotherapy and PCT turns out really high, which
is very confusing as there are no bacteria involved. (R5, 4y)
Trustworthiness
If I document that the patient has (increased) CRP but the PCT is only 0.27, he has no fever or other clinical signs of
infection, I can quit antibiotics, − it helps me to be legally sound with regard to that decision (R8, 23y)
Very many patients get antibiotics “just in case”, as we say, but after we got PCT; it is absolutely a decision aid that
helps us being “brave enough” to stop antibiotics or to not start antibiotics. (R4, 25y)
I think it is most useful to give backing in a decision. (R10, 16y)
Support decisions Diagnostic
value
She had a CRP at 300 and high fever and all sepsis criteria, she also had an increased PCT, but it didn’t matter, she
would have gotten antibiotics either way. (R13, 4y)
If I am quite convinced it is not an infection, but request a PCT and it turns out positive, I dismiss it and say like “no,
I don’t think it is an infection’ and base my decision on the clinical picture (R5, 4y)
The clinical picture was already enough for us to continue antibiotics (despite of low PCT), we would never stop
antibiotics on that clinical appearance (septic cancer patient) (R6, 4y)
Clinical evaluation
most important
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look at the CLINICAL APPEARANCE; you know, and
what kind of disease is it? Where is the infection? There-
fore, I do not base all my decisions on it” (R11, 22). One
informant, however, reported on an episode in which a
high PCT overruled the clinical picture and led to the
prolonged use of antibiotics: “We expected the PCT to be
low based on the clinical picture, but it was high, so we
continued with antibiotics, even though the clinical pic-
ture was not convincing of infection” (R14, 1y).
Discussion
This study has shown that physicians experience a
knowledge gap related to the use of PCT, which acts as
an important barrier to optimal use. The physicians,
however, perceived PCT to be a helpful tool in clinical
decision making, but the most crucial factor for anti-
biotic prescription remained their clinical assessment of
the patient.
A lack of clear guidelines on how to use PCT and
the relatively short-term experience with PCT were
factors the physicians pointed out to, a least partly,
explain the knowledge gap. This gap barricaded for
optimal use as it resulted in the use of PCT in clin-
ical issues in which it had not been validated. For in-
stance, the physicians questioned the trustworthiness
of PCT when they used the test for focal infections,
although such use is not recommended in the litera-
ture [6]. Moreover, the physicians found PCT helpful
to decide whether or not to initiate antibiotics and in
differentiating infections from, e.g., cancer and
rheumatic disorders, neither of which are recom-
mended by the literature [20]. To date, respiratory
tract infections (RTI) and sepsis are the only diagno-
ses in which meta-studies confirm the benefits of rou-
tine PCT use. In RTI, PCT is recommended to guide
the decision to withhold or stop antibiotics and, for
sepsis, to guide the discontinuation of antibiotics [21].
Moreover, despite the literature stating that PCT can-
not be trusted in all diagnoses, some physicians had
lost faith in the test due to a mismatch between the
PCT results and their clinical assessment. The varying
recommendations across studies (e.g., indications, tim-
ing, and cut-off values) may furthermore complicate
rather than clarify the optimal use of PCT [22]. Even
experienced physicians requested “a clear manual.”
Recently, two consensus reports on PCT-guided anti-
biotic therapy have been published and provide up-
dated recommendations [23, 24]. Both of these
reports recommend individualising decisions by evalu-
ating PCT cut-off values together with disease sever-
ity, setting (hospital department), clinical evaluation,
and other test findings (e.g., microbiological). The
recommendations are comprehensive and thus not
straight forward from a full-time clinicians’
perspective.
Another explanatory factor of the knowledge gap, and
thus the suboptimal PCT use, is that there was no on-
going PCT implementation at the time of this study. Re-
cent real-world studies have shown diverging results that
underline the role of active implementation. One study,
in which there had been no PCT implementation, found
increased days of antibiotics in the patients whom the
physicians had used PCT [25]. On the contrary, other
studies, in which PCT implementation was a part of an
ASP, found significantly decreased antibiotic days of
therapy [26, 27]. These findings, combined with our
study physicians’ call for more explicit guidance, high-
light a need for enforced PCT implementation with
clear-cut instructions.
Our finding of perceived usefulness of PCT for other
indications than recommended in guidelines underscores
a need for education on the current evidence, but also
the need for further studies into the potential role of
PCT in other diagnoses, such as cancer [6].
Systematic reviews on the determinants of antibiotic
prescription commonly report that physicians prescribe
excess antibiotics due to anxiety about overlooking se-
vere infections [28–30]. In our study, several informants
emphasised that PCT could limit such anxiety and thus
promote a more rational antibiotic prescription. The in-
formants experienced that PCT could not replace other
tests or clinical judgment, but they still valued it as a
diagnostic adjunct.
Adherence to PCT algorithms is commonly low, but
explanatory factors remain relatively unknown [11, 31].
Given the well-documented reduction in inappropriate
antibiotic use by adherence to PCT algorithms, optimis-
ing adherence should be prioritised [7, 8]. In the current
study, two factors were identified that might provide ex-
planatory insight into low adherence. First, uncertainty
about interpretation may result in the prescription of an-
tibiotics “just in case,” thus overruling PCT algorithms.
Secondly, clinical judgement is regarded as a more crit-
ical factor for an antibiotic decision than the PCT value.
Both elements align with studies where physicians, when
feeling a clinical uncertainty, have prescribed antibiotics
despite the PCT value being low [31, 32]. However, stud-
ies have failed to show any independent association be-
tween patient clinical severity and PCT algorithm
compliance [10, 11]. Consequently, low adherence can-
not be explained solely by the severity of patients’ clin-
ical condition, but may instead be driven by the
identified knowledge gap of when and how to use PCT.
A logical consequence may be that ASP teams should
increase their attention towards a targeted education on
when PCT is indicated and when it is not. Also, the
team should allocate time to fulfil their paramount role
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in active guidance and follow-up of physicians during
implementation.
While the qualitative design of our study has enabled
us to pinpoint areas that need more focus and poten-
tially can optimise ASP practices, the study also has
some limitations. First, we did our research at a single
centre, and other perspectives might have been identi-
fied in different settings, e.g. in hospitals having used
PCT for a prolonged period or with physicians more
thoroughly trained in PCT use than ours. However, for
many hospitals where PCT is a new diagnostic commod-
ity, we think the present study is relevant. At least in a
Norwegian context, our findings are expected to make a
difference as judged by an aforementioned national sur-
vey of PCT use in hospitals. Although many Norwegian
centres use PCT, an evaluation of its clinical usefulness
was seldom performed. Also, in most hospitals, utilisa-
tion of PCT for clinical diagnostic indications seems to
be far more prevalent than for antibiotic stewardship
purposes. We assume that a similar situation may exist
even in other countries.
Secondly, the primary investigators (ICs) familiarity
with some of the informants may have affected their re-
sponses. However, a deliberate process of reflexivity was
deployed to limit the influence of IC’s position.
Conclusion
The physicians valued PCT as a decision aid in antibiotic
prescribing. Still, uncertainty about the test acted as a
barrier for optimal use, which may be remedied by
straight forward PCT guidelines and rigorous education
and support of the physicians in future antimicrobial
stewardship efforts.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12879-020-05246-6.
Additional file 1. Additional file
1_Point_of_care_questionnaire_PCT_use: Point of care questionnaire of
the uses and consequences of PCT use.
Additional file 2.Additional file 2_Interview_guide: Interview guide.
Abbreviations
AMR: Antimicrobial resistance; ASP: Antimicrobial stewardship program;
PCT: Procalcitonin; RTI: Respiratory tract infections
Acknowledgements
We wish to thank all of the participating physicians.
Authors’ contributions
IC developed the interview guide, made appointments with the participants,
performed, and transcribed the interviews, coded and analysed the material,
and wrote the initial article draft. LPJJ developed the interview guide, coded,
and analysed the interview transcripts. JBH read the transcriptions and
approved of the final themes through several meetings with IC and LPJJ. DB
and JVB both gave crucial input throughout the process. All authors took a
substantial part in the writing and approved of the final article.
Authors’ information
JBH is the chief of infection and prevention control at the study hospital. DB
and JVB are both part of antimicrobial stewardship programs.
Funding
The study was funded by the Østfold Hospital Trust.
Availability of data and materials
The datasets supporting the conclusions of this article are available from the
corresponding author on reasonable request. They are not deposited in a
public repository as the transcripts could potentially reveal identifiable
information.
Ethics approval and consent to participate
The Regional Committees for Medical and Health Research Ethics (2018/1935
A) and the hospitals privacy appeal board (public 18/06887) approved the
study. Physicians’ signed informed consent which guaranteed confidentiality




The authors declare that they have no competing interests.
Author details
1Department of INFECTION Control, Østfold Hospital Trust, Kalnes, Norway.
2Faculty of Medicine, University of Oslo, PhD Program Medicine and Health
Sciences, Oslo, Norway. 3Department of Infectious Diseases, Oslo University
Hospital, Oslo, Norway. 4Oslo University, Faculty of Medicine, Institute of
Clinical Medicine, Oslo, Norway. 5Department of Microbiology, Oslo
University Hospital, Oslo, Norway. 6Faculty of Health and Social Studies,
Østfold University College, Fredrikstad, Norway. 7Department of Science,
Østfold Hospital Trust, Kalnes, Norway.
Received: 23 March 2020 Accepted: 10 July 2020
References
1. Jee Y, Carlson J, Rafai E, Musonda K, Huong TTG, Daza P, Sattayawuthipong
W, Yoon T. Antimicrobial resistance: a threat to global health. Lancet Infect
Dis. 2018;18(9):939–40.
2. European Council. Council conclusions on the next steps under a One
Health approach to combat antimicrobial resistance. 2016. https://www.
consilium.europa.eu/en/press/press-releases/2016/06/17/epsco-conclusions-
antimicrobial-resistance/#. (February 20th, 2020 last accessed).
3. Dyar OJHB, Schouten J, Pulcini C. What is antimicrobial stewardship? Clin
Microbiol Infect. 2017;23(11):793–8.
4. Meisner M. Update on procalcitonin measurements. Ann Lab Med. 2014;
34(4):263–73.
5. Schuetz P, Wirz Y, Sager R, Christ-Crain M, Stolz D, Tamm M, Bouadma L,
Luyt CE, Wolff M, Chastre J, et al. Procalcitonin to initiate or discontinue
antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev.
2017; (pagination).
6. Sager R, Kutz A, Mueller B, Schuetz P. Procalcitonin-guided diagnosis and
antibiotic stewardship revisited. BMC Med. 2017;15(1):15.
7. Hey J, Thompson-Leduc P, Kirson NY, Zimmer L, Wilkins D, Rice B, Iankova I,
Krause A, Schonfeld SA, DeBrase CR, et al. Procalcitonin guidance in patients
with lower respiratory tract infections: a systematic review and meta-
analysis. Clin Chem Lab Med. 2018;56(8):1200–9.
8. Iankova I, Thompson-Leduc P, Kirson NY, Rice B, Hey J, Krause A, Schonfeld
SA, DeBrase CR, Bozzette S, Schuetz P. Efficacy and safety of procalcitonin
guidance in patients with suspected or confirmed sepsis: a systematic
review and meta-analysis. Crit Care Med. 2018;46(5):691–8.
9. National Action Plan to Combat Antibiotic Resistance in the Health Services.
Oslo, Norway, The Ministry of Health and Care Services, 2016; 2016. p. I-1171 B.
10. Hohn A, Balfer N, Heising B, Hertel S, Wiemer JC, Hochreiter M,
Schroder S. Adherence to a procalcitonin-guided antibiotic treatment
protocol in patients with severe sepsis and septic shock. Ann Intensive
Care. 2018;8(1):68.
Christensen et al. BMC Infectious Diseases          (2020) 20:515 Page 6 of 7
11. Ammar AA, Lam SW, Duggal A, Neuner EA, Bass SN, Guzman JA, Wang XF,
Han X, Bauer SR. Compliance with procalcitonin algorithm antibiotic
recommendations for patients in medical intensive care unit.
Pharmacotherapy. 2017;37(2):177–86.
12. Huang DT, Yealy DM, Filbin MR, Brown AM, Chang CH, Doi Y, Donnino MW,
Fine J, Fine MJ, Fischer MA, et al. Procalcitonin-guided use of antibiotics for
lower respiratory tract infection. N Engl J Med. 2018;379(3):236–49.
13. Hulscher M, Prins JM. Antibiotic stewardship: does it work in hospital
practice? A review of the evidence base. Clin Microbiol Infect. 2017;23(11):
799–805.
14. Charani E, Holmes A. Antibiotic stewardship-twenty years in the making.
Antibiotics (Basel). 2019;8(1):7.
15. Davey P, Marwick CA, Scott CL, Charani E, McNeil K, Brown E, Gould IM,
Ramsay CR, Michie S. Interventions to improve antibiotic prescribing
practices for hospital inpatients. Cochrane Database Syst Rev. 2017;2.
https://doi.org/10.1002/14651858.CD14003543.pub14651854.
16. Shah N, Castro-Sanchez E, Charani E, Drumright LN, Holmes AH. Towards
changing healthcare workers’ behaviour: a qualitative study exploring non-
compliance through appraisals of infection prevention and control
practices. J Hosp Infect. 2015;90(2):126–34.
17. Skodvin B, Aase K, Charani E, Holmes A, Smith I. An antimicrobial
stewardship program initiative: a qualitative study on prescribing practices
among hospital doctors. Antimicrob Resist Infect Control. 2015;4:24.
18. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol.
2006;3(2):77–101.
19. Barrett AKA, Johnston J. How to … be reflexive when conducting
qualitative research. Clin Teach. 2020;17:9.
20. Lam SW, Bauer SR, Duggal A. Procalcitonin-based algorithms to initiate or
stop antibiotic therapy in critically ill patients: is it time to rethink our
strategy? Int J Antimicrob Agents. 2016;47(1):20–7.
21. Rhee C. Using procalcitonin to guide antibiotic therapy. Open Forum Infect
Dis. 2017;4(1):249.
22. Schuetz P, Bolliger R, Merker M, Christ-Crain M, Stolz D, Tamm M, Luyt CE,
Wolff M, Schroeder S, Nobre V, et al. Procalcitonin-guided antibiotic therapy
algorithms for different types of acute respiratory infections based on
previous trials. Expert Rev Anti-Infect Ther. 2018;16(7):555–64.
23. Bartoletti M, Antonelli M, Bruno Blasi FA, Casagranda I, Chieregato A,
Fumagalli R, Girardis M, Pieralli F, Plebani M, Rossolini GM, et al.
Procalcitonin-guided antibiotic therapy: an expert consensus. Clin Chem
Lab Med. 2018;56(8):1223–9.
24. Schuetz P, Beishuizen A, Broyles M, Ferrer R, Gavazzi G, Gluck EH, Gonzalez
Del Castillo J, Jensen JU, Kanizsai PL, Kwa ALH, et al. Procalcitonin (PCT)-
guided antibiotic stewardship: an international experts consensus on
optimized clinical use. Clin Chem Lab Med. 2019;57(9):1308–18.
25. Chu DC, Mehta AB, Walkey AJ. Practice patterns and outcomes associated
with procalcitonin use in critically ill patients with sepsis. Clin Infect Dis.
2017;64(11):1509–15.
26. Broyles MR. Impact of procalcitonin-guided antibiotic management on
antibiotic exposure and outcomes: real-world evidence. Open Forum Infect
Dis. 2017;4(4):ofx213.
27. Langford BJ, Beriault D, Schwartz KL, Seah J, Pasic MD, Cirone R, Chan A,
Downing M. A real-world assessment of procalcitonin combined with
antimicrobial stewardship in a community ICU. J Crit Care. 2020;57:130–3.
28. Teixeira Rodrigues A, Roque F, Falcao A, Figueiras A, Herdeiro MT.
Understanding physician antibiotic prescribing behaviour: a systematic
review of qualitative studies. Int J Antimicrob Agents. 2013;41(3):203–12.
29. Warreman EB, Lambregts MMC, Wouters RHP, Visser LG, Staats H, van Dijk E,
de Boer MGJ. Determinants of in-hospital antibiotic prescription behaviour:
a systematic review and formation of a comprehensive framework. Clin
Microbiol Infect. 2019;25(5):538–45.
30. Krockow EM, Colman AM, Chattoe-Brown E, Jenkins DR, Perera N, Mehtar S,
Tarrant C. Balancing the risks to individual and society: a systematic review
and synthesis of qualitative research on antibiotic prescribing behaviour in
hospitals. J Hosp Infect. 2019;101(4):428–39.
31. de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, Loef
BG, Dormans T, van Melsen GC, Kluiters YC, et al. Efficacy and safety of
procalcitonin guidance in reducing the duration of antibiotic treatment in
critically ill patients: a randomised, controlled, open-label trial. Lancet Infect
Dis. 2016;16(7):819–27.
32. O'Riordan F, Shiely F, Byrne S, O'Brien D, Palmer B, Dahly D, O'Connor TM,
Curran D, Fleming A. An investigation of the effects of procalcitonin testing
on antimicrobial prescribing in respiratory tract infections in an Irish
university hospital setting: a feasibility study. J Antimicrob Chemother. 2019;
74(11):3352–61.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Christensen et al. BMC Infectious Diseases          (2020) 20:515 Page 7 of 7
